Mar 21, 2019
BioInvent Unveils Broad Anti-TNFR2 Program to Treat Solid Tumors
Dec 18, 2018
IFM Therapeutics Announces Newly Discovered Mechanism of Inflammatory Processes in the Body
Dec 17, 2018
Bayer Updates Betaseron (interferon beta-1b) Prescribing Information in Accordance with the U.S. Food and Drug Administration's Pregnancy and Lactation Labeling Rule
Dec 04, 2018
Multiple Sclerosis (MS) Market Analysis, Market size, Epidemiology, Leading Companies and Competitive Analysis by DelveInsight
Oct 08, 2018
New Efficacy and Safety Data on MS Portfolio to Be Presented at ECTRIMS 2018
Jul 30, 2018
IFM Therapeutics Announces New Publication in Nature Reviews Drug Discovery Examining NLRP3 as a Target in Serious Inflammatory and Immune-Mediated Diseases
Jul 25, 2018
Medicenna Strengthens Empowered Cytokine(TM) Platform with Notice of Allowance of US Patent
Jun 06, 2018
Partner Therapeutics (PTx) Announces US FDA Approval of Leukine® (sargramostim) for the Treatment of Acute Radiation Syndrome
May 18, 2018
Growth Factors (Blood and Tissue) - 2018 Global Strategic Business Report Analysis & Forecasts (2016-2024) - Burgeoning Global Population Offers Significant Growth Opportunities
May 11, 2018
Novartis announces FDA approval of Gilenya® as the first disease-modifying therapy for pediatric relapsing multiple sclerosis
May 11, 2018
FDA expands approval of Gilenya to treat multiple sclerosis in pediatric patients
Apr 27, 2018
Bolder BioTechnology Announces Positive Results from Phase 1 Clinical Trial of BBT-015, a Long-Acting G-CSF Analog, in Healthy Volunteers
Apr 13, 2018
EMD Serono Highlights Commitment to Advance Multiple Sclerosis Treatment with Investigational Cladribine Tablets and Rebif® Data at AAN 2018
Feb 20, 2018
Kancera AB (publ) Reports Positive Results from a Phase I Study in Healthy Subjects With its Lead Immunoregulating Drug Candidate KAND567
Dec 20, 2017
New Research Demonstrates Direct Link between Inflammasome Activation and Amyloid-b Pathology in Alzheimer's Disease
Dec 07, 2017
John Walsh, M.D. Joins EMD Serono as Vice President of Neurology & Immunology, US Medical Affairs
Dec 07, 2017
Erythropoietin Drugs Market Value to Reach US$19,379.2 Million by the end of 2025: Transparency Market Research
Nov 17, 2017
Multiple Sclerosis: KOL Insight 2016
Oct 30, 2017
Psoriasis Drugs Market Size Worth $21.44 Billion by 2022 | CAGR: 9.3%: Grand View Research, Inc.
Oct 28, 2017
Novartis pivotal data show children and adolescents with relapsing MS had an 82% lower relapse rate with fingolimod vs. interferon beta-1a